here are 4 mass. biotechs making noise at the ash conference so far.
.
schneider said that he is "not aware of any relevant risk of the drug" and that his team has "not observed side effects in thousands of treated animals.".
people
.
'indian ip and liabilities law barrier to pharma r&d investment'